DeckTherapeutics is a biotechnology company that develops treatments for stroke and other acute organ injuries. The company’s technology platform is based on the development of omega- therapeutics that are intended to prevent paralysis and death after stroke. The company’s lead product candidate is THDG, a neuroprotectant with potential uses in a range of hypoxic-ischemic brain injuries. THDG was developed at Columbia University and is the cornerstone of DeckTherapeutics’ pipeline. However, the company’s technology platform was featured in The Wall Street Journal